{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T18:59:44Z","timestamp":1790794784628,"version":"4.1.0"},"reference-count":69,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,22]],"date-time":"2020-01-22T00:00:00Z","timestamp":1579651200000},"content-version":"am","delay-in-days":355,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.autrev.2018.07.014","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T13:07:51Z","timestamp":1545052071000},"page":"123-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies"],"prefix":"10.1016","volume":"18","author":[{"given":"Laurent","family":"Peyrin-Biroulet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Demarest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Nirula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2018.07.014_bb0005","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.12187","article-title":"Development and validation of a patient-reported disability measurement tool for patients with inflammatory bowel disease","volume":"37","author":"Allen","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.autrev.2018.07.014_bb0010","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1177\/1756283X14558193","article-title":"Current, new and future biological agents on the horizon for the treatment of inflammatory bowel diseases","volume":"8","author":"Amiot","year":"2015","journal-title":"Therap Adv Gastroenterol"},{"issue":"5","key":"10.1016\/j.autrev.2018.07.014_bb0015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/nrgastro.2016.208","article-title":"Current and emerging therapeutic targets for IBD","volume":"14","author":"Neurath","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0020","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa1203572","article-title":"Ustekinumab induction and maintenance therapy in refractory Crohn's disease","volume":"367","author":"Sandborn","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.07.014_bb0025","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S0140-6736(02)08512-4","article-title":"Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial","volume":"359","author":"Hanauer","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.07.014_bb0030","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1136\/gut.2006.106781","article-title":"Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial","volume":"56","author":"Sandborn","year":"2007","journal-title":"Gut"},{"key":"10.1016\/j.autrev.2018.07.014_bb0035","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.07.014_bb0040","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.07.014_bb0045","doi-asserted-by":"crossref","unstructured":"B.G. Feagan, W.J. Sandborn, G. D'Haens, J. Panes, A. Kaser, M. Ferrante, et al., Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study, Lancet 2017;389:1699\u20131709.","DOI":"10.1016\/S0140-6736(17)30570-6"},{"key":"10.1016\/j.autrev.2018.07.014_bb0050","doi-asserted-by":"crossref","first-page":"S808","DOI":"10.1016\/S0016-5085(16)32732-9","article-title":"Mo1890 Safety, Tolerability and Efficacy of E6011, Anti-Human Fractalkine Monoclonal Antibody, in the First-in-Patient Study for Crohn's Disease","volume":"150","author":"Matsuoka","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.autrev.2018.07.014_bb0055","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1056\/NEJMoa050516","article-title":"Infliximab for induction and maintenance therapy for ulcerative colitis","volume":"353","author":"Rutgeerts","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.autrev.2018.07.014_bb0060","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0140-6736(17)30930-3","article-title":"Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial","volume":"390","author":"Vermeire","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.autrev.2018.07.014_bb0065","doi-asserted-by":"crossref","unstructured":"S. Vermeire, S. O'Byrne, M. Keir, M. Williams, T.T. Lu, J.C. Mansfield, et al., Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial, Lancet 2014;384:309\u201318.","DOI":"10.1016\/S0140-6736(14)60661-9"},{"key":"10.1016\/j.autrev.2018.07.014_bb0070","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/1756283X16638833","article-title":"Predicting durable response or resistance to antitumor necrosis factor therapy in inflammatory bowel disease","volume":"9","author":"Kopylov","year":"2016","journal-title":"Therap Adv Gastroenterol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0075","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1038\/ctg.2015.63","article-title":"Loss of response to anti-TNFs: Definition, epidemiology, and management","volume":"7","author":"Roda","year":"2016","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0080","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.drudis.2015.02.008","article-title":"Bispecific antibodies","volume":"20","author":"Kontermann","year":"2015","journal-title":"Drug Discov Today"},{"key":"10.1016\/j.autrev.2018.07.014_bb0085","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/19420862.2016.1268307","article-title":"The making of bispecific antibodies","volume":"9","author":"Brinkmann","year":"2017","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-015-0227-0","article-title":"Bispecific antibodies and their applications","volume":"8","author":"Fan","year":"2015","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0095","first-page":"1","article-title":"Advances in bispecific antibodies engineering: Novel concepts for immunotherapies","volume":"6","author":"Spasevska","year":"2015","journal-title":"J Blood Disord Transfus"},{"key":"10.1016\/j.autrev.2018.07.014_bb0100","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1038\/nrd4478","article-title":"Bispecific antibodies rise again","volume":"13","author":"Garber","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.autrev.2018.07.014_bb0105","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.molimm.2015.01.003","article-title":"Alternative molecular formats and therapeutic applications for bispecific antibodies","volume":"67","author":"Spiess","year":"2015","journal-title":"Mol Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0110","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3389\/fimmu.2016.00394","article-title":"Immunoglobulin Fc heterodimer platform technology: from design to applications in therapeutic antibodies and proteins","volume":"7","author":"Ha","year":"2016","journal-title":"Front Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0115","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1380-2933(97)00067-5","article-title":"New protein engineering approaches to multivalent and bispecific antibody fragments","volume":"3","author":"Pluckthun","year":"1997","journal-title":"Immunotechnology"},{"key":"10.1016\/j.autrev.2018.07.014_bb0120","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: hope and hype","volume":"2","author":"Nelson","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0125","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/nbt0297-159","article-title":"Design and production of novel tetravalent bispecific antibodies","volume":"15","author":"Coloma","year":"1997","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0130","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1080\/19420862.2015.1113360","article-title":"Pharmacokinetic properties of IgG and various Fc fusion proteins in mice","volume":"8","author":"Unverdorben","year":"2016","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0135","doi-asserted-by":"crossref","first-page":"653","DOI":"10.4161\/mabs.21379","article-title":"Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies","volume":"4","author":"Klein","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0140","first-page":"675","article-title":"Antibody therapeutics, antibody engineering, and the merits of protein stability","volume":"11","author":"Demarest","year":"2008","journal-title":"Curr Opin Drug Discov Devel"},{"key":"10.1016\/j.autrev.2018.07.014_bb0145","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1080\/19420862.2015.1048411","article-title":"Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity","volume":"7","author":"van Schie","year":"2015","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0150","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1208\/s12248-013-9497-z","article-title":"Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics","volume":"15","author":"Xue","year":"2013","journal-title":"AAPS J"},{"key":"10.1016\/j.autrev.2018.07.014_bb0155","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1007\/s10875-013-9915-0","article-title":"Autoantibodies to variable heavy (VH) chain Ig sequences in humans impact the safety and clinical pharmacology of a VH domain antibody antagonist of TNF-alpha receptor 1","volume":"33","author":"Holland","year":"2013","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0160","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/cei.12680","article-title":"Specificity of human anti-variable heavy (VH) chain autoantibodies and impact on the design and clinical testing of a VH domain antibody antagonist of tumour necrosis factor-alpha receptor 1","volume":"182","author":"Cordy","year":"2015","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0165","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1002\/pro.3240","article-title":"Computational design of a specific heavy chain\/\u03ba light chain interface for expressing fully IgG bispecific antibodies","volume":"26","author":"Froning","year":"2017","journal-title":"Protein Sci"},{"key":"10.1016\/j.autrev.2018.07.014_bb0170","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1126\/science.1144603","article-title":"Anti-inflammatory activity of human IgG4 antibodies by dynamic Fab arm exchange","volume":"317","author":"van der Neut Kolfschoten","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.autrev.2018.07.014_bb0175","doi-asserted-by":"crossref","first-page":"452","DOI":"10.3390\/antib2030452","article-title":"Developments and challenges for mAb-based therapeutics","volume":"2","author":"Goswami","year":"2013","journal-title":"Antibodies"},{"key":"10.1016\/j.autrev.2018.07.014_bb0180","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1038\/nrgastro.2015.52","article-title":"The unusual suspects--innate lymphoid cells as novel therapeutic targets in IBD","volume":"12","author":"Goldberg","year":"2015","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0185","doi-asserted-by":"crossref","first-page":"200","DOI":"10.4049\/jimmunol.192.Supp.200.9","article-title":"Development of human B-lymphocyte targeted bi-specific DART\u00ae molecules for the treatment of autoimmune disorders (THER5P.830)","volume":"192","author":"Chen","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0190","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1136\/annrheumdis-2016-eular.4079","article-title":"Safety, tolerability, and functional activity of MGD010, a DART\u00ae molecule targeting CD32B and CD79B, following a single dose administration in healthy volunteers","volume":"75","author":"Pandya","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.07.014_bb0195","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/art.27477","article-title":"Therapeutic control of B cell activation via recruitment of Fcgamma receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold","volume":"62","author":"Veri","year":"2010","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.07.014_bb0200","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.clim.2008.05.001","article-title":"Systemic administration of an Fcgamma-Fc(epsilon)-fusion protein in house dust mite sensitive nonhuman primates","volume":"128","author":"Van Scott","year":"2008","journal-title":"Clin Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0205","doi-asserted-by":"crossref","first-page":"11098","DOI":"10.1074\/jbc.M111.283705","article-title":"Ligation of cytotoxic T lymphocyte antigen-4 to T cell receptor inhibits T cell activation and directs differentiation into Foxp3+ regulatory T cells","volume":"287","author":"Karman","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.autrev.2018.07.014_bb0210","article-title":"A bispecific protein capable of engaging CTLA-4 and MHCII protects non-obese diabetic mice from autoimmune diabetes","volume":"8","author":"Zhao","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.autrev.2018.07.014_bb0215","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.coi.2016.02.006","article-title":"Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection","volume":"40","author":"Zhukovsky","year":"2016","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0220","doi-asserted-by":"crossref","first-page":"863","DOI":"10.4161\/onci.20592","article-title":"A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)","volume":"1","author":"Stone","year":"2012","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.autrev.2018.07.014_bb0225","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.autrev.2018.07.014_bb0230","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1200\/JCO.2014.59.1586","article-title":"Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of patients with Relapsed\/Refractory Non-Hodgkin Lymphoma: final results from a phase I Study","volume":"34","author":"Goebeler","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0235","doi-asserted-by":"crossref","DOI":"10.1038\/srep17943","article-title":"A novel, native-format bispecific antibody triggering T-cell killing of B-cells is robustly active in mouse tumor models and cynomolgus monkeys","volume":"5","author":"Smith","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.autrev.2018.07.014_bb0240","doi-asserted-by":"crossref","first-page":"287ra70","DOI":"10.1126\/scitranslmed.aaa4802","article-title":"Anti-CD20\/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies","volume":"7","author":"Sun","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.autrev.2018.07.014_bb0245","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/PPO.0000000000000035","article-title":"Managing cytokine release syndrome associated with novel T cell-engaging therapies","volume":"20","author":"Maude","year":"2014","journal-title":"Cancer J"},{"key":"10.1016\/j.autrev.2018.07.014_bb0250","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2018.07.014_bb0255","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/art.11487","article-title":"Single and combined inhibition of tumor necrosis factor, interleukin-1, and RANKL pathways in tumor necrosis factor-induced arthritis: effects on synovial inflammation, bone erosion, and cartilage destruction","volume":"50","author":"Zwerina","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.07.014_bb0260","unstructured":"R.R. Barrett, L.S. Johnson, S. Singh, K. Last-Barney, D.-T. Shih, P. Giblin, et al., Compound targeting il-23a and tnf-alpha and uses thereof, US Patent No. 14\/844,338."},{"key":"10.1016\/j.autrev.2018.07.014_bb0265","unstructured":"R.L. Millican Jr, N. Seo, S. Na and C.B. Beidler, Anti-TNF\u2212\/anti-IL-23 bispecific antibodies, US Patent No 9,718,884."},{"key":"10.1016\/j.autrev.2018.07.014_bb0270","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1002\/ibd.20148","article-title":"Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance","volume":"13","author":"Mudter","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.autrev.2018.07.014_bb0275","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1093\/protein\/gzv034","article-title":"AZ17: a new bispecific drug targeting IL-6 and IL-23 with potential clinical use--improves psoriasis in a human xenograft transplantation model","volume":"28","author":"Stenderup","year":"2015","journal-title":"Protein Eng Des Sel"},{"key":"10.1016\/j.autrev.2018.07.014_bb0280","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/ard.2006.055111","article-title":"Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial","volume":"66","author":"Weinblatt","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.autrev.2018.07.014_bb0285","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1002\/art.20221","article-title":"Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate","volume":"50","author":"Genovese","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.autrev.2018.07.014_bb0290","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/nri2761","article-title":"Therapeutic antibodies for autoimmunity and inflammation","volume":"10","author":"Chan","year":"2010","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0295","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1111\/j.1476-5381.2009.00190.x","article-title":"Therapeutic antibodies: successes, limitations and hopes for the future","volume":"157","author":"Chames","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0300","doi-asserted-by":"crossref","first-page":"314","DOI":"10.4161\/self.1.4.13904","article-title":"Immunogenicity of protein therapeutics: the key causes, consequences and challenges","volume":"1","author":"Baker","year":"2010","journal-title":"Self Nonself"},{"key":"10.1016\/j.autrev.2018.07.014_bb0305","unstructured":"Food and Drug Administration, Guidance for industry. S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals, in: Editor (Ed.)^(Eds.), Book Guidance for industry. S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals, 1997, pp."},{"key":"10.1016\/j.autrev.2018.07.014_bb0310","doi-asserted-by":"crossref","first-page":"431","DOI":"10.2174\/138920108786786394","article-title":"Monoclonal antibodies--regulatory challenges","volume":"9","author":"Schneider","year":"2008","journal-title":"Curr Pharm Biotechnol"},{"key":"10.1016\/j.autrev.2018.07.014_bb0315","unstructured":"Food and Drug Administration, Points to consider in the manufacture and testing of monoclonal antibody products for human use, in: Editor (Ed.)^(Eds.), Book Points to consider in the manufacture and testing of monoclonal antibody products for human use, 1997, pp."},{"key":"10.1016\/j.autrev.2018.07.014_bb0320","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/cts.12459","article-title":"Clinical Pharmacology and Translational Aspects of Bispecific Antibodies","volume":"10","author":"Trivedi","year":"2017","journal-title":"Clin Transl Sci"},{"key":"10.1016\/j.autrev.2018.07.014_bb0325","doi-asserted-by":"crossref","first-page":"182","DOI":"10.4161\/mabs.4.2.19000","article-title":"Dual targeting strategies with bispecific antibodies","volume":"4","author":"Kontermann","year":"2012","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0330","unstructured":"Food and Drug Administration, Guidance for Industry. Codevelopment of two or more new investigational drugs for use in combination., in: Editor (Ed.)^(Eds.), Book Guidance for Industry. Codevelopment of two or more new investigational drugs for use in combination., 2013, pp."},{"key":"10.1016\/j.autrev.2018.07.014_bb0335","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/9781444318418.ch2","article-title":"Heterogeneity of inflammatory bowel diseases","volume":"2010","author":"Karp","year":"2010","journal-title":"Inflammatory Bowel Disease, Wiley-Blackwell, Oxford, UK"},{"key":"10.1016\/j.autrev.2018.07.014_bb0340","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1080\/19420862.2017.1392425","article-title":"Personalized medicine with biologics for severe type 2 asthma: current status and future prospects","volume":"10","author":"Godar","year":"2018","journal-title":"MAbs"},{"key":"10.1016\/j.autrev.2018.07.014_bb0345","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nri3661","article-title":"Cytokines in inflammatory bowel disease","volume":"14","author":"Neurath","year":"2014","journal-title":"Nat Rev Immunol"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218302830?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1568997218302830?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T21:13:43Z","timestamp":1761599623000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1568997218302830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":69,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S1568997218302830"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2018.07.014","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bispecific antibodies: The next generation of targeted inflammatory bowel disease therapies","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2018.07.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}